To investigate the potential roles of TLR2 and TLR4 in thrombosis in MPN, we observed that MPN patients activated by the TLR2 agonist (PM3CSK4) exhibited a significantly higher LPI response compared to activation by the TLR4 agonist (LPS), with mean ± SE values of 21.39 ± 1.07 and 12.12 ± 2.16, respectively (P  < 0.01). The gene discussed is TLR2; the disease is myeloproliferative neoplasm.